Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
Authors:
- Lore MerdrignacLMLore Merdrignac
- Charlotte Laniece DelaunayCDCharlotte Laniece Delaunay
- Nuno VerdascaNVNuno Verdasca
- Lorena Vega‐PirisLVLorena Vega‐Piris
- Joan O'DOnnellJOJoan O'DOnnell
- Camino Trobajo‐SanmartínCTCamino Trobajo‐Sanmartín
- Silke BudaSBSilke Buda
- Mariëtte HooiveldMHMariëtte Hooiveld
- Ana Paula RodriguesARAna Paula Rodrigues
- Gergő TúriGTGergő Túri
- Neus Latorre‐MargalefNLNeus Latorre‐Margalef
Open Access
- 10 November 2024
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70009
Abstract
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.Keywords
All Related Versions
Funding Information
- European Centre for Disease Prevention and Control (ECDC/2021/019)
This publication has 12 references indexed in Scilit:
- Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare SystemNature Communications, 2024
- Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024Vaccine, 2024
- Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control studyJournal of Infection, 2024
- Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control studymedRxiv, 2024
- COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022Eurosurveillance, 2024
- Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024Eurosurveillance, 2024
- Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024MMWR. Morbidity and Mortality Weekly Report, 2024
- Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressureThe Lancet Infectious Diseases, 2023
- GISAID: Global initiative on sharing all influenza data – from vision to realityEurosurveillance, 2017
- A simulation study of the number of events per variable in logistic regression analysisJournal of Clinical Epidemiology, 1996